Search results
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 1 day ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 2 days agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks via Yahoo Finance· 2 days agoThe revenue decline, as expected, was due to a steep drop in revenues from its COVID-19 products,...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 4 days agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
Pfizer profits drop on lower Covid-19 product sales
Digital Journal· 2 days agoPfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and...
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To...
Benzinga via Yahoo Finance· 2 days agoOn Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year...
Why Pfizer Stock Blasted More Than 6% Higher Today
Motley Fool via Yahoo Finance· 2 days agoThe Covid effect not as damaging as feared For its first quarter, Pfizer reported before market open, the pharmaceutical giant took in just under $14.9...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 2 days agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 1 day agoModerna (MRNA) beat Wall Street's first-quarter expectations Thursday. The Covid vaccine maker came...
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
BioPharma Dive via Yahoo Finance· 2 days agoSales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first...